Pharmacogenetics is the science of pharmacological response and its modification by hereditary influence; psychopharmacogenetics is the application of pharmacogenetics to the field of psychiatry.

Keywords: psychopharmacology; polymorphism; pharmacokinetics; pharmacodynamics; pharmacogenomics


Arranz MJ, Munro J, Birkett J, et al. (2000) Pharmacogenetic prediction of clozapine response. The Lancet 355: 1615–1616.

Detera‐Wadleigh SD (2001) Lithium‐related genetics of bipolar disorder. Annals of Medicine 33: 272–285.

Kawanishi Y, Tachikawa H and Suzuki T (2000) Pharmacogenomics and schizophrenia. European Journal of Pharmacology 410: 227–241.

Lin KM (2001) Biological differences in depression and anxiety across races and ethnic groups. Journal of Clinical Psychiatry 62: 13–19.

Masellis M, Basile VS, Ozdemir V, et al. (2000) Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biological Psychiatry 47: 252–266.

Pickar D and Rubinow K (2001) Pharmacogenomics of psychiatric disorders. Trends in Pharmacological Sciences 22: 75–83.

Pirmohamed M and Park BK (2001) Genetic susceptibility to adverse drug reactions. Trends in Pharmacological Sciences 22: 298–305.

Scharfetter J (2001) Dopamine receptor polymorphisms and drug response in schizophrenia. Pharmacogenomics 2: 251–261.

Weizman A and Weizman R (2000) Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. Pharmacogenomics 1: 335–341.

Wong ML and Licinio J (2001) Research and treatment approaches to depression. Nature Reviews Neuroscience 2: 343–351.

Further Reading

Bader JS (2001) The relative power of SNPs and haplotype as genetic markers for association tests. Pharmacogenomics 2: 11–24.

Cargill M and Daley GQ (2000) Mining for SNPs: putting the common variants–common disease hypothesis to the test. Pharmacogenomics 1: 27–37.

Harris S and Foord SM (2000) Transgenic gene knock‐outs: functional genomics and therapeutic target selection. Pharmacogenomics 1: 433–443.

Ingelman‐Sundberg M (2001) Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. Journal of Internal Medicine 250: 186–200.

Martinez D, Broft A and Laruelle M (2001) Imaging neurochemical endophenotypes: promises and pitfalls. Pharmacogenomics 2: 223–237.

Phillips KA, Veenstra DL, Oren E, Lee JK and Sadee W (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. Journal of the American Medical Association 286: 2270–2279.

Roses AD (2002) Pharmacogenetics place in modern medical science and practice. Life Sciences 70: 1471–1480.

Rothstein MA and Epps PG (2001) Ethical and legal implications of pharmacogenomics. Nature Reviews Genetics 2: 228–231.

Steimer W and Potter JM (2002) Pharmacogenetic screening and therapeutic drugs. Clinica Chimica Acta 315: 137–155.

Wang X and Feuerstein GZ (2000) Suppression subtractive hybridisation: application in the discovery of novel pharmacological targets. Pharmacogenomics 1: 101–108.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Ozaki, Norio(Jul 2006) Psychopharmacogenetics. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1038/npg.els.0005162]